2020
DOI: 10.1002/hep.31177
|View full text |Cite
|
Sign up to set email alerts
|

New Drugs for NASH and HIV Infection: Great Expectations for a Great Need

Abstract: on behalf of the SHIVER Network In recent years, there has been an increasing number of clinical trials for the treatment of nonalcoholic steatohepatitis (NASH). People living with human immunodeficiency virus (PLWH) are commonly excluded from these studies, usually due to concerns over drug-drug interactions associated with antiretroviral therapy. The Steatohepatitis in HIV Emerging Research Network, a group of international experts in hepatology and infectious diseases, discusses our current understanding on… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
15
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 19 publications
(20 citation statements)
references
References 70 publications
(58 reference statements)
2
15
0
Order By: Relevance
“…However, at present, there are limited pharmacokinetic data on this drug in the human body, which needs further study ( Ratziu et al, 2016 ). On 11 May 2020, Genfit announced that in its phase III trial of Elafibranor in the treatment of NASH, the drug failed to significantly improve patients’ NASH histological symptoms, and in some cases, exacerbated hepatic fibrosis compared to placebo ( Guaraldi et al, 2020 ; Shen and Lu, 2021 ). A total of 1070 patients with NASH were randomized (2:1) to receive Elafibranor 120 mg/day or a placebo ( Guaraldi et al, 2020 ; Shen and Lu, 2021 ).…”
Section: Elafibranor (Gft505)mentioning
confidence: 99%
“…However, at present, there are limited pharmacokinetic data on this drug in the human body, which needs further study ( Ratziu et al, 2016 ). On 11 May 2020, Genfit announced that in its phase III trial of Elafibranor in the treatment of NASH, the drug failed to significantly improve patients’ NASH histological symptoms, and in some cases, exacerbated hepatic fibrosis compared to placebo ( Guaraldi et al, 2020 ; Shen and Lu, 2021 ). A total of 1070 patients with NASH were randomized (2:1) to receive Elafibranor 120 mg/day or a placebo ( Guaraldi et al, 2020 ; Shen and Lu, 2021 ).…”
Section: Elafibranor (Gft505)mentioning
confidence: 99%
“…We discarded sequencing adapters, mapped miRNAs to the reference human genome and assessed the RNA biotypes for each sample with the programs: cutadapt [18], STAR [19] and featureCounts [3,20], respectively. Data were stored with miRBase [21], and sRNAbench [22] was used for the identification of miRNAs (canonical and isomiR variants).…”
Section: Mirna Sequence Analysismentioning
confidence: 99%
“…This pathway could help the case-finding of at-risk PWH who will benefit from specialist referral for secondary fibrosis assessment, such as TE examination. The identification of PWH at a high risk for liver fibrosis is of paramount importance considering that there is no pharmacologic treatment for NAFLD-associated liver fibrosis and that PWH are excluded from most ongoing global clinical trials for NASH [53]. Future studies should focus on the longitudinal and long-term effects of the large-scale application of these models of care.…”
Section: Discussionmentioning
confidence: 99%